VNN1 Gene Could Serve As a Biomarker for Response to Corticosteroids in … – Lung Disease News


Lung Disease News

VNN1 Gene Could Serve As a Biomarker for Response to Corticosteroids in
Lung Disease News
According to study investigator Gurjit Khurana Hershey, MD, PhD, director of Asthma Research at Cincinnati Children's Hospital Medical Center, “Genome-wide analysis allowed us to identify a gene, whose expression discriminated between good and poor …

View full post on asthma – Google News

A pathophysiological approach for FeNO: A biomarker for asthma.

A pathophysiological approach for FeNO: A biomarker for asthma.

Allergol Immunopathol (Madr). 2015 Mar 18;

Authors: Ricciardolo FL, Sorbello V, Ciprandi G

Abstract
The present review is focused on literature concerning the relevance of fractional exhaled nitric oxide (FeNO) in clinical practice from a pathophysiological point of view. There is increasing evidence that asthma is a heterogeneous pathological condition characterised by different phenotypes/endotypes related to specific biomarkers, including FeNO, helpful to predict therapeutic response in selected asthmatic populations. Nowadays FeNO, a non-invasive biomarker, appears to be useful to foresee asthma developing, to recognise specific asthma phenotypes, like the eosinophilic, to ameliorate asthma diagnosis and management in selected populations and to predict standard corticosteroid and biologic therapy efficacy. In addition, FeNO assessment may also be useful in patients with allergic rhinitis in order to detect the potential involvement of eosinophilic bronchial inflammation in “case finding” subjects at risk of asthma diagnosis. Therefore, it is possible to hypothesise a future with an appropriate use of FeNO by physicians dealing with worrisome clinical issues in specific asthma phenotypes.

PMID: 25796309 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Genentech to Present at 2015 COPD & Asthma Conference on Biomarker … – Lung Disease News

Genentech to Present at 2015 COPD & Asthma Conference on Biomarker
Lung Disease News
Biotechnology company Genentech has been invited to present at the 11th Asthma & COPD conference, an annual event that will gather some of the most internationally prominent scientists, clinicians and industry leaders to discuss the latest findings on …

View full post on asthma – Google News

Bench-to-Bedside Asthma Research to Study Potential Biomarker – Newswise (press release)

Bench-to-Bedside Asthma Research to Study Potential Biomarker
Newswise (press release)
Newswise — OMAHA, Neb. – What started as basic cancer research at Creighton University has yielded promising results for diagnosing and treating asthma – and the National Institutes of Health (NIH) agrees, investing nearly $1.5 million in Creighton to

View full post on asthma – Google News